{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:14:28Z","timestamp":1781878468032,"version":"3.54.5"},"reference-count":20,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Remdesivir is an intravenous antiviral approved worldwide for the treatment of COVID\u201019 in adults and children. Remdesivir, as a prodrug inhibitor of RNA polymerase, undergoes intracellular activation to form the active metabolite along with 2 inactive circulating metabolites, GS\u2010704277 and GS\u2010441524. Based on drug\u2013drug interaction (DDI) risks identified in\u00a0vitro, three Phase 1 crossover DDI studies were conducted to evaluate remdesivir as a potential (i) object, (ii) inhibitor, or (iii) inducer of enzymes and transporters. As an object of organic anion transporting polypeptide (OATP) 1B1\/1B3 and P\u2010glycoprotein inhibition (cyclosporine A), remdesivir and GS\u2010704277 exposures increased 2\u2010fold and 3\u2010fold, respectively, while GS\u2010441524 was unchanged. Increased exposures were not clinically relevant as remdesivir and GS\u2010704277 exposures remained transient (approximately 1\u2010h half\u2010life) and were unlikely to affect the formation of the active metabolite. As an object of strong cytochrome P450 (CYP) 3A induction (carbamazepine), exposure changes of remdesivir and its metabolites were not clinically significant. As an inhibitor, single\u2010dose remdesivir did not impact pitavastatin (OATP1B1\/1B3 substrate) exposures but increased midazolam (CYP3A substrate)\n                    <jats:italic>C<\/jats:italic>\n                    <jats:sub>max<\/jats:sub>\n                    (29%) to a greater extent than AUC\n                    <jats:sub>inf<\/jats:sub>\n                    (20%). Given that remdesivir exposures are transient, CYP3A inhibitory effects were similarly transient and were not clinically relevant. As an inducer with midazolam (CYP3A substrate), multiple\u2010dose remdesivir did not decrease exposures but rather transiently increased midazolam exposures to a similar degree as observed in the inhibition study. Remdesivir may be coadministered with other medications without restrictions.\n                  <\/jats:p>","DOI":"10.1111\/cts.70395","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:31:06Z","timestamp":1762957866000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Characterization of Drug\u2013Drug Interactions for Remdesivir, an Intravenous Antiviral for SARS\u2010CoV\u20102, in Healthy Participants"],"prefix":"10.1111","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5645-0014","authenticated-orcid":false,"given":"Jack","family":"Chang","sequence":"first","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aryun","family":"Kim","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Humeniuk","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed A.","family":"Shaik","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0315-7906","authenticated-orcid":false,"given":"Helen","family":"Winter","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi\u2010Chi","family":"Peng","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deqing","family":"Xiao","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazin","family":"Abdelghany","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Llewellyn","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Davies","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kandace","family":"Golden","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuguang","family":"Chen","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8473-8285","authenticated-orcid":false,"given":"Robert H.","family":"Hyland","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luzelena","family":"Caro","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Centers for Disease Control and Prevention \u201cCDC Museum COVID\u201019 Timeline \u201daccessed May 8 2025 https:\/\/www.cdc.gov\/museum\/timeline\/covid19.html."},{"key":"e_1_2_9_3_1","unstructured":"World Health Organization \u201cTimeline: WHO's COVID\u201019 Response \u201daccessed May 8 2025 https:\/\/www.who.int\/emergencies\/diseases\/novel\u2010coronavirus\u20102019\/interactive\u2010timeline."},{"key":"e_1_2_9_4_1","unstructured":"United Nations \u201cWHO Chief Declares End to COVID\u201019 as a Global Health Emergency \u201daccessed May 8 2025 https:\/\/news.un.org\/en\/story\/2023\/05\/1136367."},{"key":"e_1_2_9_5_1","unstructured":"\u201cVEKLURY (Remdesivir) [Package Insert] \u201dGilead Sciences Inc. 2025."},{"key":"e_1_2_9_6_1","article-title":"Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID\u201019","volume":"78","author":"Bhimraj A.","year":"2022","journal-title":"Clinical Infectious Diseases"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-00984-5"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00602-21"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/v17060836"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12840"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph14070655"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.918083"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2021.114118"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000485516"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1047"},{"key":"e_1_2_9_16_1","unstructured":"\u201cInternational Council for Harmonisation of Technical Requirements for Human Use \u201dDrug Interaction Studies M12 accessed August 29 2025 https:\/\/database.ich.org\/sites\/default\/files\/ICH_M12_Step4_Guideline_2024_0521_0.pdf."},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae333"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae631.2187"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.08.013"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.30.7.795"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2006.07.001"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T10:42:48Z","timestamp":1763980968000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1111\/cts.70395"],"URL":"https:\/\/doi.org\/10.1111\/cts.70395","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"2025-07-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70395"}}